Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A
Istituto di Endocrinologia, University of Pisa, Italy.
J Clin Endocrinol Metab. 1994 Apr;78(4):826-9. doi: 10.1210/jcem.78.4.8157706.
To assess whether routine measurement of serum calcitonin (CT) could improve the preoperative diagnosis of sporadic medullary thyroid carcinoma (MTC), 1385 consecutive patients presenting for nodular thyroid disease during the year 1991 were submitted to serum CT determination and fine needle aspiration cytology (FNAC). The clinical diagnosis was nontoxic nodular goiter in 1197 (86.4%) patients, toxic multinodular goiter in 65 (4.7%), autonomously functioning thyroid nodule (AFTN) in 64 (4.6%), and autoimmune thyroid disease (Graves' disease or Hashimoto's thyroiditis) with nodule(s) in 59 (4.3%). As controls, 177 patients with nonnodular thyroid disease and 32 normal subjects were also studied. Patients with FNAC suspicious of any kind of thyroid carcinoma and patients with elevated basal and pentagastrin-stimulated serum CT, regardless of the results of FNAC, were submitted to surgery. Eight (0.57%) patients (7 with nontoxic nodular goiter and 1 with AFTN) had elevated basal serum CT levels, ranging between 55-10,000 pg/mL. The pentagastrin test was abnormal in all of them. FNAC was suggestive of MTC in 2, thyroid carcinoma in 1, benign nodule in 3, and inadequate in 2. By histology, immunohistochemistry, and Northern blot analysis of total tumor RNAs, MTC was confirmed in all patients, including the 1 with AFTN, who had the association of microfollicular adenoma and a small MTC in the same lobe. After surgery, serum CT decreased to undetectable levels in 7 patients and remained undetectable in 6 of them during a mean follow-up of 22 months, although 1 of them had a positive response to pentagastrin. Forty-four patients in the group with normal serum CT levels had FNAC suspicious for differentiated thyroid carcinoma and were treated by surgery. Differentiated thyroid carcinoma, mostly papillary, was confirmed at histology in 43 subjects (3.1% of all thyroid nodules). In conclusion, the results of our study indicate that serum CT measurement is useful for the screening of sporadic MTC in patients with thyroid nodule(s). The prevalence of MTC, diagnosed by serum CT measurement in a 12-month period, among an unselected series of 1385 patients with nodular thyroid disease was surprisingly high: 0.57% of all thyroid nodules and 15.7% of all thyroid carcinomas. Serum CT measurement was superior to FNAC in suggesting the diagnosis of MTC and was devoid of falsely positive results. Increasing the diagnostic accuracy helped the surgeon to perform more radical treatment of MTC, thus achieving frequent normalization of postoperative serum CT levels. Whether this result indicates definitive cure remains to be established on the basis of longer follow-up.(ABSTRACT TRUNCATED AT 400 WORDS)
为评估血清降钙素(CT)的常规检测能否改善散发性甲状腺髓样癌(MTC)的术前诊断,1991年连续收治的1385例甲状腺结节疾病患者接受了血清CT检测及细针穿刺细胞学检查(FNAC)。临床诊断为1197例(86.4%)患者为非毒性结节性甲状腺肿,65例(4.7%)为毒性多结节性甲状腺肿,64例(4.6%)为自主性功能性甲状腺结节(AFTN),59例(4.3%)为伴有结节的自身免疫性甲状腺疾病(Graves病或桥本甲状腺炎)。作为对照,还研究了177例非结节性甲状腺疾病患者和32例正常受试者。FNAC怀疑为任何类型甲状腺癌的患者以及基础和五肽胃泌素刺激后血清CT升高的患者,无论FNAC结果如何,均接受手术治疗。8例(0.57%)患者(7例非毒性结节性甲状腺肿和1例AFTN)基础血清CT水平升高,范围在55 - 10000 pg/mL之间。他们所有人的五肽胃泌素试验均异常。FNAC提示2例为MTC,1例为甲状腺癌,3例为良性结节,2例结果不充分。通过组织学、免疫组化及肿瘤总RNA的Northern印迹分析,所有患者均确诊为MTC,包括1例AFTN患者,其同一叶内有微小滤泡性腺瘤和小MTC并存。手术后,7例患者血清CT降至检测不到水平,平均随访22个月期间,其中6例一直未检测到,尽管其中1例对五肽胃泌素有阳性反应。血清CT水平正常组中有44例患者FNAC怀疑为分化型甲状腺癌并接受了手术治疗。组织学确诊43例为分化型甲状腺癌,大多为乳头状癌(占所有甲状腺结节的3.1%)。总之,我们的研究结果表明,血清CT检测有助于筛查甲状腺结节患者中的散发性MTC。在1385例未选择的甲状腺结节疾病患者系列中,通过血清CT检测在12个月内诊断出的MTC患病率惊人地高:占所有甲状腺结节的0.57%,占所有甲状腺癌的15.7%。血清CT检测在提示MTC诊断方面优于FNAC,且无假阳性结果。提高诊断准确性有助于外科医生对MTC进行更彻底的治疗,从而使术后血清CT水平经常恢复正常。基于更长时间的随访,这一结果是否表明最终治愈仍有待确定。(摘要截短至400字)